Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders? Export

@article{citeulike:5660533, abstract = {Abstract\ \ Research on functions and signalling pathways of insulin has traditionally focused on peripheral tissues such as muscle, fat and liver, while the brain was commonly believed to be insensitive to the effects of this hormone secreted by pancreatic beta cells. However, since the discovery some 30\ years ago that insulin receptors are ubiquitously found in the central nervous system, an ever-growing research effort has conclusively shown that circulating insulin accesses the brain, which itself does not synthesise insulin, and exerts pivotal functions in central nervous networks. As an adiposity signal reflecting the amount of body fat, insulin provides direct negative feedback to hypothalamic nuclei that control whole-body energy and glucose homeostasis. Moreover, insulin affects distinct cognitive processes, e.g. by triggering the formation of psychological memory contents. Accordingly, metabolic and cognitive disorders such as obesity, type 2 diabetes mellitus and Alzheimer's disease are associated with resistance of central nervous structures to the effects of insulin, which may derive from genetic polymorphisms as well as from long-term exposure to excess amounts of circulating insulin due to peripheral insulin resistance. Thus, overcoming central nervous insulin resistance, e.g. by pharmacological interventions, appears to be an attractive strategy in the treatment and prevention of these disorders. Enhancement of central nervous insulin signalling by administration of intranasal insulin, insulin analogues and insulin sensitisers in basic research approaches has yielded encouraging results that bode well for the successful translation of these effects into future clinical practice.}, author = {Hallschmid, M. and Schultes, B.}, citeulike-article-id = {5660533}, citeulike-linkout-0 = {http://dx.doi.org/10.1007/s00125-009-1501-x}, citeulike-linkout-1 = {http://www.springerlink.com/content/l15j236p53x2qv22}, day = {1}, doi = {10.1007/s00125-009-1501-x}, journal = {Diabetologia}, keywords = {central\_nervous\_networks, cognitive\_disorders, heart, insulin, insulin\_resistance, metabolics, pancreas}, month = {November}, number = {11}, pages = {2264--2269}, posted-at = {2009-10-29 22:58:32}, priority = {2}, title = {Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders?}, url = {http://dx.doi.org/10.1007/s00125-009-1501-x}, volume = {52}, year = {2009} }

TY - JOUR ID - citeulike:5660533 L3 - citeulike-article-id:5660533 N2 - Abstract  Research on functions and signalling pathways of insulin has traditionally focused on peripheral tissues such as muscle, fat and liver, while the brain was commonly believed to be insensitive to the effects of this hormone secreted by pancreatic beta cells. However, since the discovery some 30 years ago that insulin receptors are ubiquitously found in the central nervous system, an ever-growing research effort has conclusively shown that circulating insulin accesses the brain, which itself does not synthesise insulin, and exerts pivotal functions in central nervous networks. As an adiposity signal reflecting the amount of body fat, insulin provides direct negative feedback to hypothalamic nuclei that control whole-body energy and glucose homeostasis. Moreover, insulin affects distinct cognitive processes, e.g. by triggering the formation of psychological memory contents. Accordingly, metabolic and cognitive disorders such as obesity, type 2 diabetes mellitus and Alzheimer’s disease are associated with resistance of central nervous structures to the effects of insulin, which may derive from genetic polymorphisms as well as from long-term exposure to excess amounts of circulating insulin due to peripheral insulin resistance. Thus, overcoming central nervous insulin resistance, e.g. by pharmacological interventions, appears to be an attractive strategy in the treatment and prevention of these disorders. Enhancement of central nervous insulin signalling by administration of intranasal insulin, insulin analogues and insulin sensitisers in basic research approaches has yielded encouraging results that bode well for the successful translation of these effects into future clinical practice. IS - 11 JF - Diabetologia EP - 2269 TI - Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders? VL - 52 SP - 2264 KW - central_nervous_networks KW - cognitive_disorders KW - heart KW - insulin KW - insulin_resistance KW - metabolics KW - pancreas AU - Hallschmid, M AU - Schultes, B PY - 2009/11/01/ UR - http://dx.doi.org/10.1007/s00125-009-1501-x ER -